Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators

NCT ID: NCT06333067

Last Updated: 2025-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-11

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-label, non-randomized single-arm prospective, multi-center, self-controlled clinical study with masked evaluation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients will receive 1-2 face and/or neck and/or submental treatments (per PI discretion, 2-12 weeks apart) using the SofWave system with the Lift or/and Precise applicators.

Treatment may be administered after the enrollment and screening at the first visit, or it may occur at a later date following the enrollment and screening activities based on site scheduling availabilities.

All patients will return to the clinic for one follow-up visit at 3 months ± 2 weeks post last treatment (FU1).

Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lax Skin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lax tissue

Group Type EXPERIMENTAL

Sofwave

Intervention Type DEVICE

The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sofwave

The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SUPERB

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy female and male subjects between the ages 35-80.
2. Non-Smoker.
3. Fitzpatrick skin type I-VI.
4. Desire to lift facial lax skin, neck and/or submental and/or to lift the eyebrow area and/or improve facial wrinkles appearance.
5. Able and willing to comply with all visits, treatments and evaluation schedules and requirements.
6. Able to understand and provide written Informed Consent.
7. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment.
8. Subject agrees not to undergo any other facial cosmetic treatment for a period of 3 months following last SofWave treatment.
9. Stable weight over the last 12 weeks and throughout the duration of the study.

Exclusion Criteria

* 1\. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.

2\. Presence of any active systemic or local infections.

3\. Presence of active local skin disease that may alter wound healing.

4\. Severe solar elastosis.

5\. Currently a smoker or has a history of heavy smoking (25 cigarettes per day or more) in the past 10 years.

6\. History of chronic drug or alcohol abuse.

7\. Excessive subcutaneous fat on the cheeks.

8\. Significant scarring in the area to be treated.

9\. Severe or cystic facial acne, and/or Accutane use during past 6 months.

10\. Presence of a metal stent or implant in the facial area (dental implants and/or braces are not excluded).

11\. Inability to understand the protocol or to provide a signed informed consent.

12\. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the past 6 months; injectable (Botox or fillers) of any type within the past 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift, blepharoplasty, or brow lift (including contour threads) within the past 12 months.

13\. Taking Isotretinoin or other oral retinoid within the past 6 months; taking anti-platelet or anti-coagulant within the past 2 weeks.

14\. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Minimum Eligible Age

35 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sofwave Medical LTD

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Costal Skin & Eye Institute

La Mesa, California, United States

Site Status RECRUITING

Skin Wellness Dermatology Associates

Durham, North Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shlomit Mann, MSc

Role: CONTACT

+972-4-7800268

Ruthie Amir, MD

Role: CONTACT

+972-4-300-3164

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christopher V.Crosby, MD

Role: primary

Talasia Smith

Role: primary

(919) 294 9440

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Sofwave21

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.